Intravesically administered human defensin-5 ameliorates E. coli induced catheter associated-urinary tract infections in female SD rats
Abstract
The existing treatment approaches against urinary tract infections (UTIs) are associated with severe side effects and antimicrobial resistance. Human defensin-5 (HD-5) is an important component of the innate defense mechanism in the urinary tract. The aim of our study was to evaluate the antimicrobial potential of intravesically administered HD-5 against uropathogenic Escherichia coli (UPEC) in rat cystitis model. To the best of our knowledge, this is the first study to demonstrate the therapeutic role of exogenously administered HD-5, in UTIs. With an MIC of 60 µg/ml against UPEC, HD-5 exerted antimicrobial activity primarily by disrupting membrane integrity, leading to blebbing, release of extracellular contents, and ultimately whole-cell lysis. HD-5 administered via the intravesical route significantly reduced UPEC load by 54% in bladder and 50% in urine. H and E staining of treated bladders indicated reduced inflammation and improved architectural integrity establishing a strong anti-inflammatory potential of HD-5. Also, there was visible improvement in blood parameters like TLC, DLC, Platelets and Haemoglobin in treated animals suggesting its possible immunomodulatory role. The relative efficacy of the tested therapeutic agents was found to be in the order of intravesical HD-5 > oral ciprofloxacin > intravesical ciprofloxacin > oral HD-5 under the present experimental conditions. Interestingly, intravesical dosing of HD-5 was found to be overall effective in the present…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.